Get notified when RZLT files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Securities Litigation (new) — Plaintiffs' law firms have announced investigations into potential securities law violations related to the sunRIZE trial results, though no litigation has been commenced.
Rezolute's sunRIZE trial fails primary endpoint; FDA path uncertain, cash falls to $107.8M
Filed September 24, 2026 · Period ending June 30, 2026 · Compared to 10-K Sep 17, 2025 · ~1 min read
Key Changes
-
high
Phase 3 sunRIZE trial in congenital HI missed its primary and key secondary endpoints, and the FDA is still reviewing data with no timeline for a decision.
Business / MD&A view on EDGAR → -
high
Cash and cash equivalents fell to $10.6M, while marketable debt securities rose to $97.2M, leaving total capital resources at $107.8M.
MD&A: Liquidity verify on EDGAR → -
high
Net loss widened to $77.6M from $74.4M, and operating loss increased to $83.0M, despite a 12.5% cut in R&D spending.
Financial Statements verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FUL 10-Q) is open in full — no account needed.
Partner
Trade RZLT commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 25, 2026 · How we verify